Skip to main content
OpenTrials
Completed

NCT Number: NCT06318299

Effects of Exogenous Ketone Ester Supplementation on 3-hydroxybutyrate Concentrations in Human Cerebrospinal Fluid

It is well established that the brain is capable of consuming ketone bodies, especially during low glucose availability, e.g. fasting. Cerebral metabolism of ketone bodies depends on passage of the blood brain barrier and especially the global blood concentration of ketone bodies.

Ketone bodies can be administered exogenously, and the most commonly used in clinical trials is 3-hydroxybutyrate (3-OHB). 3-OHB is carried by simple diffusion and facilitated diffusion through several monocarboxylic acid transporters (MCTs) across the blood-brain barrier.

To our knowledge, no studies in human adults exist that concurrently measure 3-OHB concentrations in blood and cerebrospinal fluid (CSF) after ingestion or infusion of exogenous ketone supplementation, necessitating further study.

Aims:

* The 3-OHB CSF/blood ratio after oral ingestion of 30 g ketone ester - primary endpoint * The window of effect: Ketone supplementation 1 h or 2 h before CSF sampling * If concentration measurements by point-of-care testing are non-inferior to mass spectrometry * If acute 3-OHB ingestion increases plasma brain-derived neurotrophic factor (BDNF) levels

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Aarhus University Hospital

Aarhus, 8200, Denmark

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All sexes
  • Referred to undergo an elective lumbar puncture procedure in the outpatient clinic at Department of Neurology, Aarhus University Hospital.
  • Age 18-80 years
  • Written and oral consent

Exclusion criteria

  • Referred to the clinic suspecting severe neuroinflammation
  • Special diet habits, including ketogenic diet, fasting, intermittent fasting etc.
  • Daily use of insulin or other medication affecting blood glucose and/or glucose metabolism
  • Not able to speak or understand Danish and/or give written and oral consent

Treatment and study plan

Ketone ester

Dietary Supplement

Commercially available ketone ester drink (KetoneAid, Virginia, USA)

Placebo

Other

Taste and appearance matched noncaloric placebo drink

Primary outcomes

  1. 3-OHB CSF/blood ratio

    Time frame: 1-2 hours after ingestion

    After oral ingestion of 30 g ketone ester drink or placebo drink

Secondary outcomes

  1. CSF 3-OHB concentrations, POCT

    Time frame: 1-2 hours after ingestion

    After oral ingestion of 30 g ketone ester drink or placebo drink, Point-of-care testing (POCT)

  2. CSF 3-OHB concentrations, Mass Spectrometry

    Time frame: 1-2 hours after ingestion

    After oral ingestion of 30 g ketone ester drink or placebo drink, Mass Spectrometry Detection

  3. CSF glucose concentrations

    Time frame: 1-2 hours after ingestion

    After oral ingestion of 30 g ketone ester drink or placebo drink

  4. Blood 3-OHB concentrations

    Time frame: 1-2 hours after ingestion

    After oral ingestion of 30 g ketone ester drink or placebo drink, Point-of-care testing (POCT)

  5. Plasma 3-OHB concentrations

    Time frame: 1-2 hours after ingestion

    After oral ingestion of 30 g ketone ester drink or placebo drink, Mass Spectrometry Detection

  6. Blood glucose concentrations

    Time frame: 1-2 hours after ingestion

    After oral ingestion of 30 g ketone ester drink or placebo drink, Point-of-care testing (POCT)

  7. Plasma BDNF concentrations

    Time frame: 1-2 hours after ingestion

    After oral ingestion of 30 g ketone ester drink or placebo drink

  8. Blood 3-OHB concentrations

    Time frame: Before ingestion

    Before oral ingestion of 30 g ketone ester drink or placebo drink, Point-of-care testing (POCT)

  9. Plasma 3-OHB concentrations

    Time frame: Before ingestion

    After oral ingestion of 30 g ketone ester drink or placebo drink, Mass Spectrometry Detection

  10. Blood glucose concentrations

    Time frame: Before ingestion

    Before oral ingestion of 30 g ketone ester drink or placebo drink, Point-of-care testing (POCT)

  11. Plasma BDNF concentrations

    Time frame: Before ingestion

    Before oral ingestion of 30 g ketone ester drink or placebo drink

Sponsors and collaborators

Lead sponsor

University of Aarhus

Other

Collaborators

  • Aarhus University Hospital

Registry information

Acronym: KetoBrain

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Mar 19, 2024
Registry last updated
Aug 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.